Guardant Health Rally Fueled by Large Q2 Beat, Shield Screening Surge and Upgraded Guidance
Guardant Health shares leapt in after-hours trading following second-quarter 2026 results that outpaced Wall Street revenue forecasts, a raised full-year sales outlook and a standout performance in the Shield colorectal screening business. The company reported $335 million in Q2 revenue, a 44% year-over-year increase and roughly 6.4% above the cons…